101 related articles for article (PubMed ID: 2308919)
41. [Receptor status (ER and PgR) determined with histochemical and biochemical methods in breast carcinoma].
Simone G; Paradiso A; Cirillo R; Mangia A; Rella G; Wiesel S; Petroni S; De Benedictis G; De Lena M
Pathologica; 1991; 83(1086):449-59. PubMed ID: 1724316
[TBL] [Abstract][Full Text] [Related]
42. [Expression of proliferating cell nuclear antigen (PCNA) and its correlation with Ki-67, TfR, ET, PgR, pTNM in carcinoma of the breast].
Rizzo A; Crisafulli C; Maiorca A; Tuccari G
Pathologica; 1992; 84(1094):65-9. PubMed ID: 1363759
[No Abstract] [Full Text] [Related]
43. Detection of Ki-67 proliferation rate in breast cancer. Correlation with clinical and pathologic features.
Veronese SM; Gambacorta M
Am J Clin Pathol; 1991 Jan; 95(1):30-4. PubMed ID: 1987749
[TBL] [Abstract][Full Text] [Related]
44. Estrogen, progesterone receptors and proliferating activity evaluated by immunocytochemistry in breast cancer.
Campani D; De Negri F; Fabbri R; Martini L; Giani C; Squartini F; Sarnelli R
Int J Biol Markers; 1991; 6(3):144-50. PubMed ID: 1791308
[TBL] [Abstract][Full Text] [Related]
45. Immunohistochemical assessment of growth fractions in colorectal adenocarcinomas with monoclonal antibody Ki-67. Relation to clinical and pathological variables.
Lanza G; Cavazzini L; Borghi L; Ferretti S; Buccoliero F; Rubbini M
Pathol Res Pract; 1990 Oct; 186(5):608-18. PubMed ID: 2287588
[TBL] [Abstract][Full Text] [Related]
46. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival.
Pertschuk LP; Kim DS; Nayer K; Feldman JG; Eisenberg KB; Carter AC; Rong ZT; Thelmo WL; Fleisher J; Greene GL
Cancer; 1990 Oct; 66(8):1663-70. PubMed ID: 2208020
[TBL] [Abstract][Full Text] [Related]
47. Ki67 index and S-phase fraction in human breast carcinomas. Comparison and correlations with prognostic factors.
Vielh P; Chevillard S; Mosseri V; Donatini B; Magdelenat H
Am J Clin Pathol; 1990 Dec; 94(6):681-6. PubMed ID: 2244589
[TBL] [Abstract][Full Text] [Related]
48. Steroid receptor status, proliferation and metallothionein expression in primary invasive ductal breast cancers.
Surowiak P; Paluchowski P; Wysocka T; Wojnar A; Zabel M
Pathol Oncol Res; 2004; 10(4):207-11. PubMed ID: 15619641
[TBL] [Abstract][Full Text] [Related]
49. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer.
Rudolph P; Alm P; Heidebrecht HJ; Bolte H; Ratjen V; Baldetorp B; Fernö M; Olsson H; Parwaresch R
J Natl Cancer Inst; 1999 Feb; 91(3):271-8. PubMed ID: 10037106
[TBL] [Abstract][Full Text] [Related]
50. Comparative evaluation of ER-ICA and enzyme immunoassay for the quantitation of estrogen receptors in breast cancer.
Hanna W; Mobbs BG
Am J Clin Pathol; 1989 Feb; 91(2):182-6. PubMed ID: 2464923
[TBL] [Abstract][Full Text] [Related]
51. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells.
Ghebeh H; Tulbah A; Mohammed S; Elkum N; Bin Amer SM; Al-Tweigeri T; Dermime S
Int J Cancer; 2007 Aug; 121(4):751-8. PubMed ID: 17415709
[TBL] [Abstract][Full Text] [Related]
52. Thymidine labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis.
Rudas M; Gnant MF; Mittlböck M; Neumayer R; Kummer A; Jakesz R; Reiner G; Reiner A
Breast Cancer Res Treat; 1994; 32(2):165-75. PubMed ID: 7865846
[TBL] [Abstract][Full Text] [Related]
53. A comparison between Ki-67 antibody reactivity and other pathological variables in breast carcinoma.
Bilous AM; McKay M; Milliken J
Pathology; 1991 Oct; 23(4):282-5. PubMed ID: 1664511
[TBL] [Abstract][Full Text] [Related]
54. Correlation of growth fraction by Ki-67 immunohistochemistry with histologic factors and hormone receptors in operable breast carcinoma.
Gasparini G; Dal Fior S; Pozza F; Bevilacqua P
Breast Cancer Res Treat; 1989 Dec; 14(3):329-36. PubMed ID: 2482095
[TBL] [Abstract][Full Text] [Related]
55. A comparative study of histopathology, hormone receptors, peanut lectin binding, Ki-67 immunostaining, and nucleolar organizer region-associated proteins in human breast cancer.
Di Stefano D; Mingazzini PL; Scucchi L; Donnetti M; Marinozzi V
Cancer; 1991 Jan; 67(2):463-71. PubMed ID: 1985739
[TBL] [Abstract][Full Text] [Related]
56. Immunohistochemical determination of growth fraction in human tumors.
Matsumura K; Tsuji T; Shinozaki F; Sasaki K; Takahashi M
Pathol Res Pract; 1989 Jun; 184(6):609-13. PubMed ID: 2780432
[TBL] [Abstract][Full Text] [Related]
57. Progesterone receptor determined by immunocytochemical and biochemical methods in human breast cancer.
Gasparini G; Pozza F; Dittadi R; Meli S; Cazzavillan S; Bevilacqua P
J Cancer Res Clin Oncol; 1992; 118(7):557-63. PubMed ID: 1378057
[TBL] [Abstract][Full Text] [Related]
58. Comparative analysis of methods for accurate recognition of cells through nuclei staining of Ki-67 in neuroblastoma and estrogen/progesterone status staining in breast cancer.
Markiewicz T; Wisniewski P; Osowski S; Patera J; Kozlowski W; Koktysz R
Anal Quant Cytol Histol; 2009 Feb; 31(1):49-62. PubMed ID: 19320193
[TBL] [Abstract][Full Text] [Related]
59. MUC3 and MCA serum levels and steroid receptor content in breast cancer.
Quaranta M; Coviello M; Daniele A; Abbate I; Durrant LG; Paradiso A; Schittulli F
Int J Biol Markers; 2004; 19(2):109-14. PubMed ID: 15255542
[TBL] [Abstract][Full Text] [Related]
60. Immunolocalisation of cytochrome P-450 3A enzymes in human breast carcinoma: relationship with tumour differentiation and steroid receptors.
Galant C; Gala JL; Van Den Berge V; Berlière M; Haumont E; Horsmans Y
Pharmacol Toxicol; 2001 Mar; 88(3):142-6. PubMed ID: 11245409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
